Do you know the benefits, risks and feasibility of providing intensive glycemic control based on Gliclazide MR?

Thanks to the ADVANCE Trial, we now know that an intensive glucose control - based on incremental titration of Gliclazide MR and other therapies - is able to reduce HbA1c levels to 6.5% effectively and consistently through time in patients with type 2 diabetes, thus achieving long-term protection. This approach significantly reduced the risk of microvascular events (non-fatal MI, non-fatal stroke and cardiovascular death) and microvascular events (retinopathy and nephropathy) by 10%, in addition to demonstrating a very good safety profile with a low hypoglycemia risk and without any other side effects.​

To know more : Click here